As cancer care becomes increasingly personalized, choosing the right molecular technology is more critical than ever. Meridian’s latest white paper, From Single Mutations to Whole Genomes, offers a comparative look at qPCR, targeted NGS, and whole-genome sequencing—highlighting their roles in enabling earlier detection, therapy selection, and long-term monitoring across the cancer care continuum.

This paper outlines the key technical trade-offs and emerging trends shaping oncology assay design. It explores how precision oncology is transforming cancer care—driving demand for highly sensitive, accurate assays across the care continuum. To meet these evolving needs, the next generation of diagnostics will rely on flexible, scalable platforms and ambient-temperature stable reagents that deliver reliable performance wherever testing is needed.